December 15, 2023 02:27 PM EST

FDA converts accelerated to full approval for Padcev-Keytruda combo in bladder cancer

Zachary Brennan

Senior Editor

The FDA on Friday granted full approval to Seagen and Astellas Pharma’s Padcev (enfortumab vedotin-ejfv) in combo with Merck’s Keytruda (pembrolizumab) for patients with locally …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA converts accelerated to full approval for Padcev-Keytruda combo in bladder cancer

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CagriSema’s weight loss data disappointed. What does Novo do next?

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA con­verts ac­cel­er­at­ed to full ap­proval for Pad­cev-Keytru­da com­bo in blad­der can­cer

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA converts accelerated to full approval for Padcev-Keytruda combo in bladder cancer

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CagriSema’s weight loss data disappointed. What does Novo do next?

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings